<DOC>
	<DOCNO>NCT00898040</DOCNO>
	<brief_summary>RATIONALE : Studying sample tissue patient cancer laboratory may help doctor learn change may occur DNA identify biomarkers related cancer . PURPOSE : This laboratory study look DNA sample patient multiple myeloma .</brief_summary>
	<brief_title>Study DNA Samples From Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether increased frequency 1 polymorphic allele associate clinical endpoint use custom myeloma single nucleotide polymorphism ( SNP ) chip analysis bank DNA sample patient multiple myeloma . - Determine SNPs associate toxicity cause , variation tumor cell genetics , individual genetic variation affect drug activation , distribution , metabolism , export ( ADME ) . - Determine SNPs associate response , influence ADME . - Determine SNPs associate bone disease ( variable ) among patient multiple myeloma . - Determine SNPs associate epidemiology ( i.e. , risk factor development multiple myeloma ) . OUTLINE : This retrospective , multicenter study . Banked DNA sample analyze use custom single nucleotide polymorphism ( SNP ) chip ass approximately 3,590 SNPs 1,061 gene associate myeloma growth response . PROJECTED ACCRUAL : A total 600 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma DNA sample bank ECOG study ( clinical trial group [ e.g. , SWOG MRC ] ) PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>